As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026. Dr. Ute Schleyer, Vice President, Internal Project Management and EHS Sustainability, Vetter, provides key insights on how bio/pharmaceutical companies and their suppliers are collaborating and the sustainability frameworks supporting these efforts.

DCAT Value Chain Insights’ Production to Prescription podcast features thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance. ICYMI, other recent episodes in 2026 include: 

• 2026 Outlook: CDMO Market for Injectables, featuring Ian Tzeng, Managing Director and Partner, L.E.K. Consulting and lead of L.E.K.’s Pharmaceutical Contract Services Practice (February 2026)

• 2026: Drugs To Watch: The Year Ahead, featuring Matthew Arnold, Principal Analyst and Content Strategist, Clarivate (January 2026)

For the full list of recent episodes and to listen, click here